Iceland· IS-EU/1/99/117/003-004
Synagis
A palivizumab product containing palivizumabum inn, registered in Iceland by AstraZeneca AB*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Palivizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Palivizumab · ATC J06BD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palivizumab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palivizumab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$51.40
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Palivizumabum INN
- Manufacturer
- AstraZeneca AB*
- Country
- Iceland (IS)
- ATC code
- J06BD01
- ATC class
- Palivizumab
- Defined daily dose
- 3.75 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean9839411 ml x1 glasISK 120201
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwaySynagisAstraZeneca
- SwitzerlandSynagis 100 mg/1 ml, InjektionslösungAstraZeneca AG
- CzechiaSYNAGISAstraZeneca AB, Södertälje
- BelgiumSynagis 100 mg/mlAstraZeneca
- SpainSYNAGIS 100 mg/1 ml SOLUCION INYECTABLEAstrazeneca Ab
- PolandSynagisAstraZeneca AB
- SwedenSynagis 100 mg/1 ml Injektionsvätska, lösningAstraZeneca AB
- FinlandSynagisAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/934b3742-f060-42a7-8eec-59580f9c32cb GET /v1/drugs/934b3742-f060-42a7-8eec-59580f9c32cb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "J06BD01",
"marketed": false,
"strength": "100 mg/ml",
"ma_number": "EU/1/99/117/003-004",
"substance": "Palivizumabum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "41873"
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.